Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China tariffs, NIH funding, and biopharmaceutical research activity, which leads the firm to lower its 2025 revenue estimate as a result. However, despite the near-term uncertainty, management remains optimistic about the 2025 prospects for newly launched products, says the analyst, who believes shares could experience multiple expansion if the company continues to execute its plan to grow the business organically, increase cash flow, and pay down debt.

Confident Investing Starts Here:

Quickly and easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on HBIO:

Disclaimer & DisclosureReport an Issue

Blade Air Mobility Reports Q1 2025 Financial Results Harvard Bioscience Earnings Call: Mixed Sentiments and Strategic Moves Harvard Bioscience reports Q1 adjusted EPS (1c) vs. 2c last year Harvard Bioscience sees Q2 revenue $18M-$20M HBIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

View Comments